Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials.
Reprod Health
; 14(Suppl 3): 172, 2017 Dec 14.
Article
em En
| MEDLINE
| ID: mdl-29297366
ABSTRACT
BACKGROUND:
For 30 years, women have sought equal opportunity to be included in trials so that drugs are equitably studied in women as well as men; regulatory guidelines have changed accordingly. Pregnant women, however, continue to be excluded from trials for non-obstetric conditions, though they have been included for trials of life-threatening diseases because prospects for maternal survival outweighed potential fetal risks. Ebola virus disease is a life-threatening infection without approved treatments or vaccines. Previous Ebola virus (EBOV) outbreak data showed 89-93% maternal and 100% fetal/neonatal mortality. Early in the 2013-2016 EBOV epidemic, an expert panel pointed to these high mortality rates and the need to prioritize and preferentially allocate unregistered interventions in favor of pregnant women (and children). Despite these recommendations and multiple ethics committee requests for their inclusion on grounds of justice, equity, and medical need, pregnant women were excluded from all drug and vaccine trials in the affected countries, either without justification or on grounds of potential fetal harm. An opportunity to offer pregnant women the same access to potentially life-saving interventions as others, and to obtain data to inform their future use, was lost. Once again, pregnant women were denied autonomy and their right to decide.CONCLUSION:
We recommend that, without clear justification for exclusion, pregnant women are included in clinical trials for EBOV and other life-threatening conditions, with lay language on risks and benefits in information documents, so that pregnant women can make their own decision to participate. Their automatic exclusion from trials for other conditions should be questioned.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Complicações Infecciosas na Gravidez
/
Ensaios Clínicos como Assunto
/
Seleção de Pacientes
/
Doença pelo Vírus Ebola
/
Vacinas contra Ebola
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Female
/
Humans
/
Pregnancy
País/Região como assunto:
Africa
Idioma:
En
Revista:
Reprod Health
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Suíça